ISCAR® MALI, ISCAR® PINI, ISCAR® QUERCUS, ISCAR® MALI SPECIAL 25mg and ISCAR® QUERCUS SPECIAL 25mg are all made from Viscum album Tr. (P-LAF). They are homeopathic, sterile injectables for subcutaneous use.
Active ingredient: Viscum album Tr. (P-LAF). Prepared according to the HPUS Class P aqueous fermentation method--1 part by weight of fresh plant material in five parts by weight of tincture. The quantity of tincture in each ampule is indicated in the section "How Supplied." Viscum album is a semi-parasitic plant that grows on different host trees. The species of the host tree is indicated by Mali = Apple tree, Pini = Pine tree and Quercus = Oak tree.
Inactive ingredients: Water for injection, sodium chloride for isotonicity.
Homeopathic.
All ISCAR® preparations are indicated as homeopathic medications for adjunct treatment of cancerous conditions, apathy, sadness, constipation and internal thermo-regulation problems. 1 Clinical experience shows that ISCAR® MALI is primarily utilized in female patients and ISCAR® QUERCUS in male patients. 6 ISCAR® PINI is used in patients of both genders, mainly when the respiratory tract or the skin is affected. 6
All ISCAR® preparations can be used during chemotherapy, hormone or radiation therapy; interactions with other drugs are unknown.
There has been no research on interactions with immune modulating drugs (i.e. Thymus extract). Concurrent use of such preparations with ISCAR® or with ISCAR® SPECIAL requires careful dosing; frequent monitoring of immune function parameters is recommended.
Information is available on mistletoe preparations similar to ISCAR® or ISCAR® SPECIAL. These findings can be summarized as follows:
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
Treatment with ISCAR® MALI SPECIAL 25mg and ISCAR® QUERCUS SPECIAL 25mg is administered in two distinct phases:
Start with 1 box of Series 0 . Beginning with the 0.05mg tincture/ml ampule inject 3 times weekly, increasing the strength sequentially. Repeat with a second box of Series 0. If well tolerated by the patient, treatment can be instituted with ISCAR® MALI SPECIAL 25mg or ISCAR® QUERCUS SPECIAL 25mg.
The maintenance phase has been reached with the switch to ISCAR® MALI SPECIAL 25mg or ISCAR® QUERCUS SPECIAL 25mg, which is injected 3 times weekly subcutaneously. Progress should be monitored on a regular basis. With marked local reactions (more than 2"/5cm in diameter) and/or temperature reactions above 100.4 °F (38 °C), treatment should be stopped until the symptoms have subsided. Afterwards, treatment is resumed with a lower dose of ISCAR® SPECIAL. This may be done by reducing the frequency of injection or by using a fraction of an ampule.
During the first year of treatment with ISCAR® SPECIAL, it is recommended to continue treatment without injection-free intervals. After the first year of treatment, the physician may recommend a 1-week injection-free interval following every sequence of 14 injections if progress is satisfactory.
Treatment with ISCAR® MALI, ISCAR® PINI and ISCAR® QUERCUS is administered in two distinct phases:
Start with 1 box of Series 0 . Beginning with the 0.05mg tincture/ml ampule inject 3 times weekly, increasing the strength sequentially, until reaching the strength which induces the individual reaction (see below). Should this not occur, repeat with second box of Series 0.
Follow with 1 box of Series I and continue, if necessary, with 1 box of Series II until the individual reaction occurs. Increasing the strength beyond Series I requires careful monitoring.
With marked local reactions (more than 2"/5cm in diameter) and/or temperature reactions above 100.4 °F (38 °C), treatment should be stopped until the symptoms have subsided, then resumed with the next lower series.
If the highest strength in Series I (50 mg tincture/ml) causes excessive local reactions, it is possible to use the individual stregth box of 5 mg tincture/ml of the particular type of ISCAR® three times weekly.
If no reaction is achieved by increasing strengths, the physician may wish to switch to a different host tree.
The maintenance phase has been reached when the individual reaction occurs (see below). It is advisable to continue with the ISCAR® series in which the reaction dose represents the highest strength. If, for example, the reaction strength is 100 mg tincture/ml, use Series II (5 mg / 50 mg / 100 mg tincture/ml). Progress should be monitored on a regular basis. Physicians may wish to intensify treatment in case of increased mental or physical stress (i.e. shorten intervals between injections).
If no observable reactions were achieved during the induction phase and changing to an ISCAR® preparation of another host tree is unsuccessful, the following treatment may be utilized:
As a complementary therapy or postoperatively, if no solid tumor is present: long term treatment with Series I .
In case of manifest tumors and no reaction to Series I: long term treatment with Series II .
The following reactions, single or in combination, indicate a positive treatment progress:
Individual Reaction: This may be recognized by at least one of the following:
Frequency of Injections and Treatment Intervals:
All types of ISCAR® are usually administered 3 times weekly. The best time tends to be in the mornings, or when the body temperature naturally rises.
After one year of treatment, if progress is satisfactory, the physician may recommend a 1-week injection-free interval following every sequence of 14 injections.
Differentiated Therapy: if progress is satisfactory, intervals may be lengthened (i.e. from 1 week to 2 weeks in the second year of treatment, 3 or 4 weeks in the third year of treatment). With manifest tumors, 10 series (7 injections each) per year should be the minimum; in other instances, a minimum of 7 series (7 injections each) a year is recommended. In certain situations, it may be advisable to give daily injections with no intervals (i.e. in advanced stages if the patient clearly feels worse on days when no injection is given).
Important: Although the above recommendations reflect common practice, the physician may recommend different dosage frequencies.
Injections of the contents of a 1-ml ampule of all types of should be given sub-cutaneously. ISCAR® works systemically, so injections are often given in the abdominal region or thigh. Some researchers believe that there may be a local effect as well, so the physician may recommend administering the injection in the vicinity of the tumor. Irradiated areas and inflamed skin areas should be avoided. The distance from the tumor should be 1.2"-1.6" (3-4 cm).
Each package contains 7 × 1-ml ampules.
When ordering, please be sure to specify both the "host" type (see under Description) and the Series, Special or Individual strength desired.
Store at controlled room temperature (15-30 °C / 60-85 °F) away from direct sunlight, except for the "Special" which should be stored in the refrigerator (4-8 °C / 39-46 °F). To avoid local irritation, hold the ampule in your hand briefly to warm up the liquid before injecting.
|
||||||||||||||||||||||||||||||||||||||||||||||||
01-081001
Made in Germany, by Weleda AG, D73525 Schwäbisch Gmünd.
Distributed by: Weleda, Inc., Congers, NY 10920